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Abstract
Context—Chronic pain impacts one-third of the U.S. population, and its effects are debilitating 
for individuals and costly to the medical system. Although opioids are commonly prescribed to 
address chronic pain, they confer risk for misuse and addiction, and may not fully restore life 
function – particularly with regard to psychosocial factors. Because of the multiplicity of impacts 
that chronic pain may have on daily functioning, broad-spectrum behavioral interventions are 
needed.
Objectives—The purpose of this study was to conduct follow-up analyses from a pilot 
randomized controlled trial of Mindfulness-Oriented Recovery Enhancement (MORE) to assess 
specific effects of MORE on various biopsychosocial aspects of pain-related impairment.
Methods—Chronic pain patients (N=115; mean age 48±14 years; 68% female) were randomly 
assigned to either eight weeks of MORE or to a support group (SG). Domains of pain-related 
functional interference were measured with the Brief Pain Inventory at pre- and post-treatment, 
and at a three-month follow-up. Treatment effects were analyzed with multivariate intention-to-
treat models.
Results—MORE participants reported significantly greater reductions in functional interference 
than SG participants at post-treatment across all domains, including: general activity, mood, 
walking ability, normal work, relationships, sleep, and enjoyment of life. These effects were 
largely maintained by the three-month follow-up; however, general activity level and walking 
ability were no longer significant, indicating differential long-term effects between physiological 
and psychological functioning.
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Conclusion—Findings demonstrate preliminary efficacy of MORE as a treatment for pain-
related functional impairments, and suggest that effects may be more pronounced and durable for 
aspects of psychological function.
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Introduction
Approximately 100 million U.S. adults are affected by chronic pain, resulting in $635 billion 
in medical costs and lost productivity each year (1). Chronic pain is increasingly understood 
as a complex biopsychosocial phenomenon associated with high rates of psychological 
distress and functional impairment (2). Because emotional and sensorial pain processes 
overlap in the brain (3), the negative emotions evoked by pain can perpetuate dysfunction 
both by increasing pain intensity and decreasing pain tolerance (2), and by contributing to 
additional somatic symptoms via ill-defined etiopathologic mechanisms (4). As a 
consequence of the neural mechanisms underlying these phenomena, individuals suffering 
with chronic pain may experience anhedonia (5) and withdraw from meaningful activities 
and relationships.
Although opioids are commonly prescribed to address chronic pain, they also confer risk for 
misuse and addiction (6). Moreover, whereas opioids may reduce pain intensity, they may 
not fully restore life function – particularly with regard to psychosocial factors. Because of 
the multiplicity of impacts that chronic pain may have on domains of functioning, new 
broad-spectrum behavioral interventions are needed. One such novel intervention is 
Mindfulness-Oriented Recovery Enhancement (MORE), a treatment that integrates 
mindfulness training, cognitive reappraisal skills, and positive emotion regulation into a 
therapeutic approach designed to ameliorate functional interference resulting from chronic 
pain and prevent addictive use of prescription opioids (7). Mindfulness training – the 
practice of cultivating a non-reactive, receptive awareness of and attention to present 
moment experiences – has been shown to reduce pain symptoms (8-10), decrease emotional 
distress (11, 12), and reduce addictive behaviors (13). Reframing the meaning of stressful 
events through cognitive reappraisal has been shown to significantly reduce negative 
emotions (14) and the urge to use addictive substances (15). Finally, positive emotion 
regulatory strategies such as savoring pleasant events may enhance positive affect and foster 
psychological resilience (16) while reducing anhedonia (17). MORE combines the 
complementary aspects of these three therapeutic elements into a broad spectrum treatment 
for chronic pain.
We recently conducted a pilot randomized controlled trial (RCT) of MORE in a sample of 
chronic pain patients who had been taking prescription opioids for more than three months 
(18). In this RCT, MORE significantly decreased opioid misuse, desire for opioids, pain 
severity, and an overall index of pain-related functional interference (18). Although this 
study revealed that MORE decreased a univariate measure of generalized functional 
interference, it has yet to be determined if MORE has differential effects on specific 
Garland et al. Page 2






















domains of pain-related impairment. For instance, given that MORE focuses on altering 
emotional responses to pain but does not provide physical therapy or education in 
kinesiology, it seems plausible that MORE might reduce the impact of pain on mood to a 
greater extent than the impact of pain on walking ability. Thus, the aim of this study was to 
conduct a secondary data analysis from the previous trial to assess the specific and 
differential effects of MORE on various biopsychosocial aspects of pain-related impairment. 
We hypothesized that, at post-treatment, chronic pain patients randomly assigned to MORE 
would exhibit significantly greater reductions across all domains of pain-related functional 
impairments than participants assigned to a conventional support group (SG), and that these 
reductions in functional impairments would be maintained at three-month follow-up. We 
additionally hypothesized that these reductions in pain-related functional interference would 
be more pronounced and durable for psychological impairments (mood, relationships, sleep, 
and enjoyment of life) than for physical impairments (activity level, work, walking ability).
Methods
Participants
Participants met inclusion criteria if they reported chronic non-cancer-related pain and had 
been prescribed and taken opioids for analgesia daily or nearly every day for at least the past 
90 days (19). Participants were recruited from primary care clinics, pain clinics, and 
neurology clinics in Tallahassee, FL through flyers and online classified ads. Fig. 1 
diagrams the study flow. Participants were assessed for comorbid psychiatric disorders with 
the Mini-International Neuropsychiatric Interview 6.0 (20) and excluded if they were 
actively suicidal or psychotic. In addition, the Current Opioid Misuse Measure (COMM; a = 
0.83) (21) was used to determine whether participants were at risk for opioid misuse, using a 
validated cut-point (COMM > 13) derived from a study of a primary care sample of opioid-
using chronic pain patients (22).
A majority of participants (68%) were women (mean age 48 years, SD 14), and more than 
half (59%) were unemployed, many because of medical disability. Participants had been in 
pain an average of 11.2 (SD 10.1) years. The most prevalent current chronic pain diagnosis 
reported by participants across both treatment conditions was low back pain (56.5%), 
followed by fibromyalgia (20.0%), arthritis (7.0%), upper back/neck pain (6.0%), or “other” 
pain conditions (10.5%). The most prevalent current psychiatric disorders were major 
depressive disorder (68.3%), generalized anxiety disorder (30.7%), alcohol use disorder 
(12.8%), post-traumatic stress disorder (11.9%), and substance use disorder (9.0%). Using 
the validated cut-point on the COMM, 72.2% of the total randomized sample was at risk for 
opioid misuse. There were no significant differences between MORE and SG participants at 
baseline on any demographic or clinical variable.
Procedures
Following screening, individuals who met eligibility criteria and consented completed a pre-
intervention assessment where they reported demographic and clinical information on 
questionnaires. Next, participants were randomly allocated to MORE or to the SG (which 
served as the active control condition). Assessors were blind to each respondent's group 
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assignment, which was concealed throughout the study. Immediately after the eight-week 
MORE or SG intervention, participants completed a post-intervention assessment including 
the same questionnaires administered at pre-treatment. Study procedures were approved by 
the Florida State University Human Subjects Committee.
MORE Intervention—Techniques drawn from mindfulness training, third-wave cognitive-
behavior therapy, and positive psychology were integrated into a manualized eight-session 
group intervention designed to address the multiplicity of pathogenic factors involved in 
chronic pain and long-term opioid use (7). MORE sessions involved: mindfulness training to 
disrupt maladaptive habits and facilitate reinterpretation of pain sensations as harmless 
sensory information; reappraisal training to regulate negative emotions and enhance the 
sense of meaning in life; and training in savoring techniques to reverse anhedonia and 
strengthen the motivation to engage in valued activities. Mindfulness training involved 
mindful breathing and body scan techniques, with an emphasis on developing metacognitive 
awareness and acceptance of physical and emotional distress. MORE participants were 
asked to engage in daily 15 minute mindfulness practice sessions at home guided by a CD 
developed by the first author. Sessions were held in groups of 8 to 12 individuals, were two 
hours in length, and were administered by a Masters-level clinical social worker who had 
practiced mindfulness for over a decade and had clinical experience offering mindfulness 
training to persons with psychiatric disorders. This individual was supervised by the first 
author (the developer of MORE and an experienced, licensed psychotherapist).
Support Group Intervention—The active control condition in this study consisted of 
eight weekly, two-hour conventional SG sessions comprised of 8 to 12 participants, in which 
a Master's level clinical social worker (different from the MORE facilitator) led discussion 
on topics pertinent to chronic pain and long-term opioid use (e.g., the experience of coping 
with chronic pain and opioid-related problems, the stigma associated with these conditions). 
This SG format was derived from the evidence-based treatment condition outlined in the 
Matrix Model treatment manual (23). SG participants disclosed feelings about group topics, 
and provided advice and emotional support to their peers. The clinician used client-centered, 
reflective listening techniques (24) but did not prescribe any specific recommendations for 
change. This intervention, which typifies a commonly-available form of conventional group 
therapy for chronic pain, was found in prior RCTs to have equivalent perceived credibility to 
mindfulness-based interventions and to decrease distress among patients with chronic pain 
(6) and addiction (25). By using a therapeutically-active control condition, our research 
design attempted to control for therapeutic expectancy, social support, and attention by a 
caring professional. SG participants were asked to engage in 15 minutes of journaling a day 
on chronic pain-related themes at home.
Fidelity Monitoring—The first author reviewed video/audio-recordings of the sessions to 
monitor therapist adherence to the MORE and SG treatment manuals via a fidelity checklist. 
Protocol deviations were corrected by the therapist in successive group sessions.
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Pain Interference—Functional interference from pain was assessed with seven items from 
the pain interference subscale of the Brief Pain Inventory (26), a well-validated measure that 
has been widely used to assess acute and chronic pain. Subjects rated on a 1 (does not 
interfere) to 10 (completely interferes) scale the extent to which pain had interfered with 
each of seven domains of normal functioning in the past week, including: general activity, 
mood, walking ability, normal work, relations with other people, sleep, and enjoyment of 
life.
Statistical Analysis
Primary analyses focused on an intention-to-treat (ITT) analysis, and we used a modified 
ITT (mITT) approach for sensitivity analysis to assess the efficacy of MORE with regard to 
reducing pain interference. Because ITT involves analysis of data from all subjects 
regardless of whether or not they completed treatment or study assessments, we included 
participants who were missing data on post-treatment and follow-up measures. ITT analyses 
were conducted on the entire randomized sample of participants who were assessed at pre-
intervention and randomized to intervention conditions (N = 115). Of this ITT sample, 88 
participants attended at least one treatment session, and 72 participants completed the 
treatments. Three participants who completed treatment were lost to post-treatment 
assessment. The mITT sample consisted of the 67 participants who attended at least five of 
the eight MORE or SG sessions and completed the post-treatment assessments.
Within the MORE group, of those individuals who attended at least one session, four 
individuals dropped out because of logistical reasons, one dropped out for an unrelated 
medical issue, two were lost to post-assessment, and five chose to discontinue the 
intervention. In the SG, three dropped out for logistical reasons, one was lost to post-
assessment, and four chose to discontinue the intervention. The majority of non-starters 
cited the time commitment to participate in the study as a major barrier to participation. The 
majority (93.0%) of non-starters reported dropping out of the trial prior to the beginning of 
treatment as a result of being unable to meet the time commitment required by study 
involvement. Non-significant t-tests and Chi-square statistics indicated there were no 
significant differences between participants who dropped out vs. those who completed the 
study across clinical or sociodemographic variables.
We performed Little's Missing Completely At Random (MCAR) test to analyze patterns of 
missing data (27). The observed pattern was consistent with data being missing completely 
at random. Consequently, hypothesis testing was conducted using a multivariate analysis of 
covariance (ANCOVA) strategy with maximum likelihood estimation of missing data 
conducted within the Analysis of Moment Structures 17.0 (AMOS 17.0) software package, a 
method that has been employed previously to assess clinical trial outcomes in studies of 
behavioral (28) and medical (29) interventions. In accordance with the classical ANCOVA 
approach endorsed by Frison and Pocock (30) for analyzing clinical trial outcomes, we 
controlled for pre-treatment differences in functional interference using the pre-
randomization measures as covariates. In the first multivariate ANCOVA model, post-
treatment values from each of the seven pain interference items were regressed on 
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intervention group (MORE vs. SG) after covarying pre-treatment values on these items and 
controlling for age, gender, education, income level, duration of pain, and baseline opioid 
misuse. A similar ANCOVA model was conducted by regressing three-month follow-up 
values on intervention group after covarying pre-treatment values. The Bonferroni-Holm 
procedure was used to prevent the inflation of type I error rate stemming from multiple 
comparisons (31). This analytic approach was repeated for the ITT and mITT samples. 
Study sample size was determined a priori based on a power analysis conducted with G-
Power software using medium-large effect size estimates derived from earlier trials 
demonstrating the effects of MORE on clinical outcomes in alcohol dependent individuals 
(32) and effects of mindfulness training in chronic pain patients (6).
Results
Effects of MORE on Domains of Functional Interference
There were no statistically significant between-group differences in baseline levels of any of 
the domains of pain-related functional interference. A multivariate model was fit to compare 
the domains of pain-related functional interference at post-treatment between MORE and 
SG participants. This model included pre-treatment levels of functional interference domains 
as well as pre-treatment opioid use disorder status and sociodemographic variables (i.e., age, 
gender, income, education, race, duration in pain, and baseline risk of opioid misuse) as 
covariates. The analysis revealed a significant effect of treatment condition, such that 
MORE patients showed significantly less functional interference at post-treatment than SG 
patients across all domains: general activity β = 1.07, SE = 0.42, P = 0.01; mood β = 1.12, 
SE = 0.48, P = 0.02; walking ability β = 1.64, SE = -0.55, P = 0.003; normal work β = 1.22, 
SE = 0.47, P = 0.01; relationships β = 1.43, SE = 0.51, P = 0.005; sleep β = 1.83, SE = 0.48, 
P < 0.001; and enjoyment of life β = 1.46, SE = 0.43, P < 0.007. All of these effects 
remained statistically significant following Holm-Bonferroni corrections for multiple 
comparisons. Greater years in pain significantly predicted less interference in relationships 
(β = -0.08, SE = 0.03, P = 0.004), sleep (β = -0.08, SE = 0.03, P = 0.004), and enjoyment of 
life (β = -0.10, SE = 0.03, P < 0.001. In contrast, neither baseline risk of opioid misuse nor 
any of the sociodemographic covariates were significantly associated with residualized 
change in domains of pain-related functional interference after correcting for multiple 
comparisons. Overall model fit was adequate, χ2/df = 1.74; IFI = 0.90; CFI = 0.89; RMSEA 
= 0.08; 95% CI = 0.06, 0.10).
A second multivariate model was fit to compare the domains of pain-related functional 
interference at three-month follow-up between MORE and SG participants. This model 
included pre-treatment levels of functional interference domains and pain duration as 
covariates, but omitted pre-treatment opioid use disorder status and sociodemographic 
predictors given their lack of significance in the first model. This model also revealed a 
significant effect of treatment condition, such that MORE patients showed significantly less 
functional interference at follow-up than SG patients across a number of domains, including 
general activity β = 1.40, SE = 0.65, P = 0.03; mood β = 2.32, SE = 0.65, P < 0.001; walking 
ability β = 1.57, SE = 0.79, P < 0.05; normal work β = 2.06, SE = 0.54, P < 0.001; 
relationships β = 2.65, SE = 0.65, P < 0.001; sleep β = 2.27, SE = 0.67, P < 0.001; and 
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enjoyment of life β = 2.62, SE = 0.65, P < 0.001. After Holm-Bonferroni corrections for 
multiple comparisons, effects on walking ability and general activity level were no longer 
significant. This model fit more poorly than the first multivariate model, χ2/df = 2.45; IFI = 
0.90; CFI = 0.89; RMSEA = 0.11; 95% CI = 0.09, 0.13). Adding sociodemographic 
variables and baseline risk of opioid misuse as model covariates did not significantly 
improve fit indices; however, a trimmed model containing only significant pathways 
between treatment group and functional interference domains fit the data well, χ2/df = 1.04; 
IFI = 0.99; CFI = 0.99; RMSEA = 0.02; 95% CI = 0.00, 0.08).
Sensitivity Analysis
Analysis of the mITT sample with the same set of covariates revealed a similar pattern of 
results to the ITT analyses presented above. Participants in MORE reported significantly 
less functional interference at post-treatment than SG participants across all domains: 
general activity (P = 0.01); mood (P = 0.02); walking ability (P = 0.003); normal work (P = 
0.01); relationships (P = 0.006); sleep (P < 0.001); and enjoyment of life (P < 0.001). 
Similarly, the mITT analysis indicated that participants in MORE had significantly less 
functional interference at follow-up than SG participants across these domains: general 
activity (P = 0.02); mood (P < 0.001); walking ability (P = 0.03); normal work (P < 0.001); 
relationships (P < 0.001); sleep (P < 0.001); and enjoyment of life (P < 0.001). Means and 
effect sizes for ITT and mITT analyses are presented in Table 1.
Intervention Feasibility/Acceptability
Both interventions were roughly comparable in terms of feasibility/acceptability. Study 
treatments were feasible to implement because of the relatively low number of therapeutic 
sessions and a comparatively little amount of required homework relative to other 
mindfulness-based interventions. There were no significant differences in the proportion of 
participants in each treatment group who dropped out prior to the end of treatment, χ2 = 
1.97, P = 0.16. Of those individuals who attended the first treatment session, 71.4% of the 
MORE group and 82.6% of the SG completed treatment. As reported earlier (18), there were 
no significant between-group differences in duration of weekly homework practice; MORE 
participants engaged in an average of 166.9 (SD 93.4) minutes of homework practice a 
week.
Discussion
The present pilot study sought to extend the findings from our original RCT of MORE by 
assessing the differential effects of the intervention on individual domains of pain-related 
impairment. While study results indicated that MORE significantly reduced adverse effects 
of chronic pain on daily life activities and decreased a wide array of functional impairments, 
the therapeutic effects of MORE tended to be more pronounced and durable for 
psychological domains than for physical domains of pain-related interference. Relative to 
the SG, MORE led to large-moderate effect size reductions in the adverse effects of chronic 
pain on relationships with others, sleep, and enjoyment of life, and moderate effect size 
improvements in general activity level, walking ability, and the capacity to perform normal 
work-related tasks both within and outside of the home. The majority of these positive 
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effects were sustained for three months following treatment. However, after correcting for 
multiple comparisons, the effects of MORE on general activity level and walking ability 
were no longer significant by three-month follow-up. This finding suggests that continued 
practice of mindfulness skills during therapist-led treatment sessions may be required to 
sustain benefits on physical functioning. Yet, with respect to the effects of MORE on pain-
related interference in aspects of psychological functioning, effect sizes increased over time 
(for instance, the small effect sizes initially observed for mood increased to large effect sizes 
by follow-up), suggesting that prolonged integration of mindfulness skills in everyday life 
outside of treatment sessions may be needed to obtain maximal benefit in these domains. 
Taken together, study findings provide important additional information about how future 
iterations of the MORE treatment could be structured to optimize treatment effects.
MORE targets cognitive-affective processes implicated in chronic pain with skills designed 
to enhance mindfulness, reappraisal, and savoring of natural rewards. By teaching 
participants to mindfully reappraise pain sensations as innocuous sensory signals, MORE 
may decrease attentional fixation on pain (34) resulting in less catastrophic appraisals of 
bodily sensations and reduced impairment stemming from somatic discomfort. Furthermore, 
by promoting the search for meaning in the context of adverse life conditions, MORE may 
foster engagement in valued activities in spite of pain. Lastly, by providing instruction in 
mindful savoring of positive events and pleasant experiences, MORE may enhance 
enjoyment of life and attenuate the emotional toll of chronic pain. To wit, recent evidence 
suggests that MORE enhances sensitivity to naturally rewarding experiences, thereby 
reducing the perceived need for opioids (17). In these ways, MORE may modulate the 
impact of chronic pain, leading to improvements in functional ability and quality of life.
Although these results are promising, limitations are inherent in the use of self-report 
measures of pain-related impairment. Future research should employ functional assessments 
of activities of daily living in order to more accurately determine the degree to which 
participation in MORE is associated with concrete improvements in functional ability. 
Moreover, the study was limited by our use of a post-treatment assessment and only one 
follow-up data point; future studies should employ more follow-up assessments and follow 
participants for more than one year post-treatment. Although study findings indicate that 
MORE may be an effective clinical approach to alleviate the functional impact of chronic 
pain, future studies should evaluate process measures, skill practice, and 
psychophysiological assessments in order to explicate the pathways by which MORE may 
positively impact functioning. Lastly, it should be acknowledged that the SG homework 
assignment of journaling on chronic pain-related themes may have fostered rumination on 
symptoms and, therefore, worsened or slowed improvement of chronic pain.
Given the high prevalence of chronic pain in the U.S. adult population and the escalating 
incidence of prescription opioid misuse, there is a growing need for new interventions that 
can address multiple domains of pain-related impairment. Moreover, as a result of advances 
in treatment, many patients with cancer and other serious illnesses are living longer with 
high levels of pain-related dysfunction and attendant psychological distress; long-term 
opioid pharmacotherapy is often used to manage such symptoms, which may increase risk 
for opioid-related complications. Findings from this analysis suggest that MORE may be a 
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useful nonpharmacologic intervention for reducing the adverse effects of chronic pain on 
biopsychosocial functioning and enhancing quality of life in the face of adversity.
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